Jiangsu Zongyi (SHA:600770) controlling shareholder Nantong Zongyi Investment plans to increase its shareholding in the company by between 50 million yuan and 100 million yuan, according to a Tuesday filing with the Shanghai bourse.
The shareholder will boost its holdings through centralized bidding on the Shanghai Stock Exchange system within one year until May 25, 2027.
Seibu Giken's (TYO:6223) consolidated Chinese subsidiary, Seibu Giken (Changshu), has received a 500 million yen order from a Chinese engineering company for VOC concentrators to be used at a major Chinese shipyard.The order was secured due to the subsidiary's proven track record in producing and selling equipment essential for ship painting processes within the Chinese market, according to a Tokyo bourse filing on Tuesday.Delivery is expected in the third quarter, though the customer name, site name and unit quantities cannot be disclosed to protect trade secrets.The sales from this order have already been included in the group's consolidated forecast for the fiscal year ending December.
Diamond Power Infrastructure (NSE:DIACABS, BOM:522163) Chief Financial Officer Samir Naik has resigned, effective May 25, citing personal reasons, according to an Indian bourse filing on Tuesday.The company has appointed Pawan Lohiya as its new chief financial officer, effective May 26, the filing said.Lohiya previously served as deputy CFO for the past two years, it added.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 2/3 trial studying pimurutamab HLX07 in combination with Hansizhuang and chemotherapy in the Chinese Mainland, according to a Tuesday filing with the Hong Kong bourse.The drug in this combination is being compared to placebo in combination with Hansizhuang or pembrolizumab and chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer.